Citing an anticompetitive agreement that was “clearly made out,” India’s Competition Commission took issue with GlaxoSmithKline and Sanofi’s operations in the country this week and fined the international pharmas nearly $10 million.
The body ordered GSK to pay $9.4 million in fines and to “cease and desist” its “collusive bidding” practices in supplying the government a meningitis vaccine for approximately 200,000 Haj pilgrims annually. Sanofi was fined about $500,000.
The complaint, focusing on the supply of polysaccharide Quadrivalent Meningococcal Meningitis vaccine, was brought by local vaccines firm Bio-Med and also implicated India’s Health and Family Welfare Ministry in the process. Each year, the Indian government solicits bids for the purchase of the vaccines that are required to be given to the Haj pilgrims.
In its finding, the competition commission said that the parties failed to establish independent business decision-making.
Full content: Seeking Alpha
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Redfin Settles $9.2M Commission Inflation Lawsuits
May 7, 2024 by
CPI
DOJ Supports Colorado’s Efforts to Block Kroger-Albertsons Merger
May 7, 2024 by
CPI
Japan Considers Regulation of AI Developers
May 7, 2024 by
CPI
European Commission Extends Decision Deadline for Ita-Lufthansa Merger
May 7, 2024 by
CPI
UK, US and Australia Sanction Senior Leader of LockBit Cybercrime Gang
May 7, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI